Three different Malaysian authorities can end up regulating the same tube of cooling gel. Which one you deal with — and whether you launch in days or in six months — is decided at the formulation bench, not on the application form.
Written & researched by Norpadilah Abd Latif, Chemist & Cosmetic Formulation Contributor · Technical input by ORIZI Group R&D Team · Fact-checked by Creaton Poh · Published by ORIZI Group · Last reviewed August 2026
Disclosure: This article is published by ORIZI Group and may refer to our own manufacturing experience, services and capabilities. External factual claims are supported by cited sources.
Quick Answer
A topical pain relief product in Malaysia is regulated in one of three ways, decided by how it works and what it claims. A cooling or warming product that works by sensation and makes no therapeutic claim is a cosmetic, notified with the National Pharmaceutical Regulatory Agency (NPRA) — the notification note is issued from the QUEST system once payment is confirmed. A product that claims pain relief, or contains an analgesic active, is a medicine needing MAL registration. A product that works by physical means, such as a cooling patch, is a medical device registered with the Medical Device Authority (MDA).
Key Takeaways
- The route follows the primary mode of action plus the claim — not the format. A cream, a gel and a patch can each fall under a different authority.
- Cosmetic notification (NOT) costs RM50 per product or variant, is valid for 2 years, and the notification note is generated from NPRA’s QUEST system once payment is confirmed.
- Medicine registration (MAL) carries an NPRA evaluation of 116 working days for a single active ingredient and 136 working days for two or more — counted only from a complete submission.
- Menthol and other sensory agents keep a product cosmetic; methyl salicylate, capsaicin and topical NSAIDs move it to the medicine route.
- Most brands lose the fast route on the label, not the formula — NPRA does not permit words referring to muscles, joints, nerves or medical conditions in the product name of a notified cosmetic.
In this guide:
- What decides which route your product takes?
- The three routes compared
- How fast is each route, really?
- Which ingredients keep you on the cosmetic route?
- What you cannot print on a cosmetic pain product
- How we screen an enquiry before quoting
- Where this goes wrong
- Frequently asked questions
Scope of this guide
This guide covers topical products applied to the skin for aching, tired or stiff areas — creams, gels, balms, sprays, roll-ons and patches — sold in Malaysia. It is written for brand owners and distributors deciding how to bring such a product to market. It does not cover oral analgesics, injectables, or products for open wounds. Regulatory positions stated here are current as of August 2026 and are drawn from the published guidelines linked in each section.
What decides which route your product takes?
Two things: the primary mode of action, and the claim.
NPRA’s classification criteria for products sitting between categories set this out directly. A drug acts by pharmacological, immunological or metabolic action in or on the body. A medical device does not achieve its primary intended action by those means, though it may be assisted by them. A cosmetic is applied to external parts of the body mainly to clean, perfume, change appearance, correct body odour, protect or keep them in good condition — and, critically, must not be presented as treating or preventing disease.
The clearest illustration comes from Malaysia’s own classification table. A heat pad or cooling pad intended “to relief aches and pains” is classified as a medical device, regulated by the MDA. A medicinal patch intended “to relieve fatigue, body aches, joint pains” is classified as a drug, regulated by NPRA. Same complaint, same body area, two different authorities — because one works by physically moving heat and the other works pharmacologically.
This is why the question “can I register a pain relief cream as a cosmetic?” has no yes-or-no answer. It depends on whether the product you are describing is still a cosmetic once you have written the label.
The three routes compared
| Route | Authority | Typical products | Governing framework |
|---|---|---|---|
| NOT — cosmetic notification | NPRA | Cooling gels, warming balms, massage creams, relief sprays and roll-ons that work by sensation | Control of Drugs and Cosmetics Regulations 1984 |
| MAL — product registration | NPRA | Medicated rubs, analgesic balms, medicinal patches, topical NSAID products | Sale of Drugs Act 1952; Control of Drugs and Cosmetics Regulations 1984 |
| MDA — device registration | Medical Device Authority | Cooling patches, hot and cold packs, supports, cold-therapy sprays acting physically | Medical Device Act 2012 (Act 737) |
If a concept genuinely sits on the boundary, the formal step is to apply to NPRA for a classification decision. NPRA issues a notification letter stating the category, and that letter is what accompanies a submission to the MDA. Guessing is the expensive option: the packaging is usually already printed by the time a misclassification surfaces.
How fast is each route, really?
This is the difference that decides whether a brand catches a trend or watches it pass.
| Route | Stated timeline | Fee / dossier | Validity |
|---|---|---|---|
| Cosmetic notification (NOT) | Notification note generated from QUEST once payment is confirmed; manufacture or import may begin on receipt | RM50 per product and variant; Product Information File held by the notification holder | 2 years, renewable |
| Medicine registration (MAL), traditional product | 116 working days for a single active ingredient; 136 working days for two or more, from a complete submission | Full quality, stability, safety and efficacy dossier; queries must be answered within the stated window | Per registration terms |
| Medical device (MDA) | Class A is a self-declaration; higher risk classes require a Conformity Assessment Body review before the MDA submission | Conformity assessment plus establishment licensing | Per registration terms |
Read the middle row carefully. 116 working days is roughly five and a half calendar months of evaluation — and the clock only starts once the submission is complete. Add formulation, stability data and any regulatory queries, and a medicated topical is realistically a year-scale project. A cosmetic-route cooling gel built on an existing base formula is a weeks-scale project.
Which ingredients keep you on the cosmetic route?
The decision is made by the actives, because the actives determine the mode of action.
| Ingredient direction | How it works | Route implication |
|---|---|---|
| Menthol, peppermint oil, eucalyptus oil | Cold sensation through thermoreceptor stimulation at the skin surface | Cosmetic route, within permitted cosmetic ingredient limits |
| Vanillyl butyl ether, ginger extract | Warming sensation, controllable by concentration | Cosmetic route |
| Methyl salicylate | Salicylate absorbed through the skin, acting pharmacologically | Medicine route |
| Capsaicin | Acts on sensory nerve pathways | Medicine route |
| Topical NSAIDs (for example diclofenac) | Anti-inflammatory pharmacological action | Medicine route |
A menthol gel still delivers the cold hit that customers use to judge whether a relief product “works”. That sensory response is the product experience, and it is available on the fast route. Adding methyl salicylate for a stronger medicated character is a legitimate choice — it is simply a different business, with a different timeline and a different dossier.
What you cannot print on a cosmetic pain product
Two separate rules catch brands here, and they are enforced independently of the formula.
The claim rule
A cosmetic product must not use a name or claims regarded as medicinal in nature or beyond the cosmetic scope, and must not be presented as treating or preventing disease. NPRA’s cosmetic claims guideline works through a five-step test covering composition, site of application, main function, product presentation and physiological effect. “Relieves muscle pain” fails the presentation test. “Cooling and refreshing for tired, hard-working legs” does not.
The product name rule
Separately, NPRA lists product names that are not permitted for a notified cosmetic. These include names referring to a disease or medical condition, and names referring to internal organs or body parts outside the cosmetic scope — the published examples include muscle, joint, nerve, chest rub, inflammation and period pain, alongside their Malay equivalents such as otot and sendi. The list is explicitly not exhaustive, and NPRA reserves the right to disallow any name it considers misleading.
The practical consequence: a product can be perfectly formulated for the cosmetic route and still be rejected because of the word chosen for the front of the pack. Names and claims should be settled before artwork goes to print, not after.
The wording rules are detailed enough to deserve their own guide: see what you can and cannot print on a pain relief label in Malaysia for NPRA’s published acceptable-versus-unacceptable claims table.
How we screen an enquiry before quoting
Based on ORIZI Group’s manufacturing experience, most pain-relief enquiries that reach us describe a cosmetic product using medicine language. The brief says “pain relief cream”, but the product being described is a menthol cooling gel for tired legs — a cosmetic that has been given a medicinal name because that is how the category is spoken about in the market.
So before we quote, we run three questions in this order:
- How does it work? If the effect is a cold or warm sensation, the cosmetic route is open. If it depends on an absorbed pharmacological active, it is not.
- What must the label say to sell? If the brand’s entire proposition rests on the words “pain relief”, the cosmetic route is closed regardless of the formula, and we say so at this point rather than after tooling.
- What is the channel and the deadline? A pharmacy-distributed medicated rub can absorb a long registration. A product built for a seasonal or social-commerce window cannot.
The output of those three questions is the route, and the route sets the formulation brief — not the other way round. In practice the second question is the one that changes projects: a brand willing to sell on sensation and use rather than on a therapeutic claim can usually be in market on the cosmetic route, and a brand unwilling to move off the claim needs to budget for a registration timeline measured in months.
Limitation: this is our screening practice as a manufacturer, not a regulatory determination. Only NPRA can classify a borderline product, and we route genuinely uncertain concepts to a formal classification application rather than deciding internally.
Where this goes wrong
- Artwork printed before the name is checked. The most common and most avoidable cost. A rejected product name means new artwork, new plates and a missed launch window.
- Marketing outrunning the notification. Advertising is assessed separately; a compliant pack undermined by a social post claiming pain relief creates the same exposure.
- Assuming a format determines the route. A patch is not automatically a device, and a cream is not automatically a cosmetic. The medicinal patch and cooling pad examples above are the proof.
- Copying a competitor’s label. The product you are copying may hold a MAL registration that permits language your notified cosmetic cannot use.
- Treating notification as approval of the formula. Notification is a declaration by the notification holder, who remains responsible for safety, the Product Information File and post-market obligations.
Frequently asked questions
Can I sell a pain relief cream in Malaysia without a MAL number?
Yes, if the product is genuinely a cosmetic — that is, it works by a sensory cooling or warming effect and its name, label and advertising make no therapeutic claim. It is then notified with NPRA as a cosmetic. If it claims to relieve pain or contains an analgesic active, it requires a MAL registration and cannot be sold on a cosmetic notification.
Is a cooling patch a cosmetic or a medical device?
A patch that works by physically drawing heat away is a medical device regulated by the MDA. Malaysia’s classification table lists a heat pad or cooling pad intended to relieve aches and pains as a medical device, while a medicinal patch relying on an absorbed active is classified as a drug.
How much does cosmetic notification cost?
RM50 for each product, and RM50 for each variant, payable through NPRA’s QUEST system. Renewal is charged at the same rate and the notification is valid for two years.
How long does a MAL registration actually take?
NPRA’s evaluation timeline for a traditional product is 116 working days for a single active ingredient and 136 working days for two or more. That period begins from a complete submission, so incomplete dossiers and unanswered queries extend it beyond the stated figure.
Can I use the word “muscle” in my product name?
Not in the product name of a notified cosmetic. NPRA’s list of non-permissible cosmetic product names includes references to body parts outside the cosmetic scope such as muscle, joint and nerve, together with disease and medical condition names. The word may still be usable in general marketing copy depending on context, which is why name and claim decisions should be reviewed together.
Who is responsible if the classification turns out to be wrong?
The notification holder or product registration holder carries the regulatory responsibility, not the contract manufacturer. That is precisely why the route should be settled in writing before production begins.
Sources & references
- NPRA — Guidelines for Control of Cosmetic Products in Malaysia — notification fee, validity period, issue of the notification note, and cosmetic claims requirements.
- NPRA — Annex I, Part 8: Guideline for Cosmetic Claims — the five-step test for deciding whether a product and its claims are cosmetic.
- NPRA — Annex I, Part 2: Non-Permissible Product Name for Cosmetic Product — the published examples of names that cannot be used.
- NPRA — Drug Registration Guidance Document, Appendix 2: Medical Device–Drug–Cosmetic Interphase — classification criteria and the heat pad, cooling pad and medicinal patch entries.
- Medical Device Authority Malaysia — guidance documents — product classification and borderline product guidance under the Medical Device Act 2012 (Act 737).
Update history
August 2026 — First published.
Next step: if you are planning a cooling gel, warming balm or relief spray, see how we manufacture on each route on our OEM pain relief and cooling gel page, or read how Malaysia handles a similar classification question for slimming products. When you are ready, send your product concept and target claims through the ORIZI Group contact page and we will confirm the route before you commit to packaging.
